These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3975177)

  • 41. Metioprim-sulphadiazine distribution in the canine prostate.
    Iversen P; Nielsen OS; Vergin H; Madsen PO
    Prostate; 1981; 2(4):327-35. PubMed ID: 7329870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM; Boeckh A; Simpson RB; Dubose K
    J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rifampin and trimethoprim distribution in normal and hydronephrotic kidney and in prostate: an experimental study in dogs.
    Frimodt-Møller N; Maigaard S
    Scand J Urol Nephrol Suppl; 1987; 104():107-13. PubMed ID: 3481458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The distribution of ciprofloxacin and its metabolites in human plasma, pulmonary and bronchial tissues.
    Bacracheva N; Scholl H; Gerova Z; Chervenakov P; Dobrev P; Vlahov V
    Int J Clin Pharmacol Ther Toxicol; 1991 Sep; 29(9):352-6. PubMed ID: 1937996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R; Wagenaar JA; Walker RD
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The intraprostatic penetration of ciprofloxacin.
    Waldron R; Arkell DG; Wise R; Andrews JM
    J Antimicrob Chemother; 1986 Apr; 17(4):544-5. PubMed ID: 2940211
    [No Abstract]   [Full Text] [Related]  

  • 48. Ciprofloxacin concentrations in tonsils following a single intravenous infusion.
    Falser N; Dalhoff A; Weuta H
    Infection; 1984; 12(5):355-7. PubMed ID: 6511090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration.
    Boothe DM; Boeckh A; Boothe HW; Wilkie S
    Vet Ther; 2001; 2(2):120-8. PubMed ID: 19753704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
    Habiyaremye I; Verbist L; Vandepitte J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):800-4. PubMed ID: 3116489
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antibacterial and antifungal agents. VI. Pirfloxacin and related compounds: synthetic and microbiological studies].
    Artico M; Corelli F; Massa S; Stefancich G; Panico S; Simonetti N
    Farmaco Sci; 1986 May; 41(5):366-80. PubMed ID: 3087770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg.
    Naber KG; Sörgel F; Kinzig M; Weigel DM
    J Urol; 1993 Nov; 150(5 Pt 2):1718-21. PubMed ID: 8411457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intraperitoneal penetration of ciprofloxacin.
    Lockley MR; Waldron R; Wise R; Donovan IA
    Eur J Clin Microbiol; 1986 Apr; 5(2):209-10. PubMed ID: 2941284
    [No Abstract]   [Full Text] [Related]  

  • 56. Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin.
    Cole LK; Papich MG; Kwochka KW; Hillier A; Smeak DD; Lehman AM
    Vet Dermatol; 2009 Feb; 20(1):51-9. PubMed ID: 19152587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Secretion of various antimicrobial substances in dogs with experimental bacterial prostatitis.
    Baumueller A; Madsen PO
    Urol Res; 1977; 5(4):215-8. PubMed ID: 22949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of lomefloxacin in the treatment of chronic prostatitis.
    Scelzi S; Travaglini F; Nerozzi S; Dominici A; Ponchietti R; Novelli A; Rizzo M
    J Chemother; 2001 Feb; 13(1):82-7. PubMed ID: 11233805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostatic tissue and secretion concentrations of rosamicin and erythromycin. Experimental studies in the dog.
    Baumueller A; Kjaer TB; Madsen PO
    Invest Urol; 1977 Sep; 15(2):158-60. PubMed ID: 903212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.